US › Healthcare

Rapport Therapeutics, Inc. Common Stock (RAPP)

US · Healthcare · Biotechnology

$42.20+3.46%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$20.0M
Net profit
$-19.9M
Profit YoY
+17.5%
EPS
$-0.42
EPS estimate
$-0.71
Net margin
-99.3%

EPS came in at -0.42 against a street estimate of -0.71 — a beat of 40.8%.

Key statistics

Market cap
$1.96B
Forward P/E
0.0
P/B
4.16
Book value
$9.86
EPS (TTM)
$-2.60
52-week high
$44.28
52-week low
$13.62
50-day MA
$39.27
200-day MA
$32.11
Beta
0.95

Analyst view

Analysts rate Rapport Therapeutics, Inc. Common Stock a strong buy (5 buy, 0 hold, 0 sell out of 5) with an average price target of $58.59.

Shareholding

Insiders
4.59%
Institutions
109.65%

Largest institutional holders

FundStake
FMR Inc15.00%
TRV GP V, LLC14.92%
ARCH VENTURE CORP7.80%
Capital Research & Mgmt Co - Division 36.48%
Cormorant Asset Management, LLC6.19%
The Goldman Sachs Group Inc6.15%
BlackRock Inc5.24%
Sofinnova Ventures3.98%

Recent filings & reports

DocumentDate
Shareholder vote results · Q2 20262026-06-10
Quarterly report · Q1 20262026-05-07
Results announced · Q2 20262026-05-07
Proxy statement · Q2 20262026-04-23
Reg FD disclosure · Q2 20262026-04-21
Annual report FY20252026-03-10
Results announced · Q1 20262026-03-10
Quarterly report · Q3 20252025-11-06

Readable in the app.

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Rapport Therapeutics, Inc. Common Stock — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.